Association of genetic factors with selected measures of physical performance

Physical Therapy

Volumn 86, Issue 4, 2006, Pages 585-591

  Thompson, William R ^a   Binder Macleod, Stuart A ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

Angiotensin converting enzyme (ACE); Genetics; Rehabilitation

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSINOGEN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN; HEXOKINASE; INSULIN; KININ; PROTEIN; RENIN; RNA;

ALLELE; CHROMOSOME; ENDURANCE; ENZYME ACTIVITY; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; PHYSICAL PERFORMANCE; PHYSIOTHERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STRENGTH;

EID: 33645559108     PISSN: 00319023     EISSN: None     Source Type: Journal    
DOI: 10.1093/ptj/86.4.585     Document Type: Review

References (55)

1. Boehm CD, Kazazian HH Jr. The molecular basis of genetic disease. Curr Opin Biotechnol. 1990;1:180-187.
2. Niklasson L, Rasmussen P, Oskarsdottir S, Gillberg C. Neuropsychiatric disorders in the 22q11 deletion syndrome. Genet Med. 2001;3:79-84.
3. Carlson BM. Embryology in the medical curriculum. Anat Rec. 2002;269:89-98.
4. Rastogi D, Rosenzweig BE, Koumbourlis A. Pulmonary hypertension in Jarcho-Levin syndrome. Am J Med Genet. 2002;107:250-252.
5. De Silva HA, Gunatilake SB, Johnston C, et al. Medial temporal lobe atrophy, apolipoprotein genotype, and plasma homocysteine in Sri Lankan patients with Alzheimer's disease. Exp Aging Res. 2005;31:345-354.
6. Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet. 2005;6:237-260.
7. Jacobsen PK. Preventing end stage renal disease in diabetic patients: genetic aspect (part I). J Renin Angiotensin Aldosterone Syst. 2005;6:1-14.
8. Rankinen T, Perusse L, Rauramaa R, et al. The human gene map for performance and health related fitness phenotypes: the 2003 update. Med Sci Sports Exerc. 2004;36:1451-1469.
9. Gayagay G, Yu B, Hambly B, et al. Elite endurance athletes and the ACE I allele: the role of genes in athletic performance. Hum Genet. 1998;103:48-50.
10. Woods DR, Humphries SE, Montgomery HE. The ACE I/D polymorphism and human physical performance. Trends Endocrinol Metab. 2000;11:416-420.
11. Folland J, Leach B, Little T, et al. Angiotensin-converting enzyme genotype affects the response of human skeletal muscle to functional overload. Exp Physiol. 2000;85:575-579.
12. Williams AG, Dhamrait SS, Wootton PT, et al. Bradykinin receptor gene variant and human physical performance. J Appl Physiol. 2004;96:938-942.
13. Karjalainen J, Kujala UM, Stolt A, et al. Angiotensin gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes. J Am Coll Cardiol. 1999;34:494-499.
14. Taylor RR, Mamotte CD, Fallen K, Van Bockxmeer FM. Elite athletes and the gene for angiotensin-converting enzyme. J Appl Physiol. 1999;87:1035-1037.
15. Rankinen T, Wofarth B, Simoneau JA, et al. No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. J Appl Physiol. 2000;88:1571-1575.
16. Alberts B, Bray D, Johnson A, et al. Essential Cell Biology. New York, NY: Garland Publishing Inc; 1998.
17. Russell P. Genetics. Redwood City, Calif: Benjamin Cummings; 2001.
18. Stryer L. Biochemistry. New York, NY: WH Freeman & Co; 2000.
19. Binder SB. ACE inhibitors: review of four new agents. Am Fam Physician. 1993;48:851-857.
20. Jan Danser AH, Schalekamp M, Bax W, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation. 1995;92:1387-1388.
21. Jones A, Montgomery HE, Woods DR. Human performance: a role for the ACE genotype? Exerc Sport Sci Rev. 2002;30:184-190.
22. Montgomery HE, Marshall R, Hemingway H, et al. Human gene for physical performance. Nature. 1998;393:221-222.
23. Myerson S, Hemingway H, Budget R, et al. Human angiotensin I-converting enzyme gene and endurance performance. J Appl Physiol. 1999;87:1313-1316.
24. Tsianos G, Sanders J, Dhamrait S, et al. The ACE gene insertion/ deletion polymorphism and elite endurance swimming. Eur J Appl Physiol. 2004;92:360-362.
25. Ohishi M, Fuji K, Minamino T, et al. A potent risk factor for restenosis. Nat Genet. 1993;5:324-325.
26. Montgomery HE, Clarkson P, Dollery CM, et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 1997;96:741-747.
27. Reneland R, Lithell H. Angiotensin-converting enzyme in human skeletal muscle: a simple in vitro assay of activity in needle biopsy specimens. Scand J Clin Lab Invest. 1994;54:105-111.
28. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
29. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation. 1995;92:1387-1388.
30. Geisterfer AT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy not hyperplasia of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749-756.
31. Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992;105:77l-772.
32. Ishigai Y, Mori T, Fukuzawa A, Shibano T. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. Am J Physiol. 1997;273:H2659-H2663.
33. Garfinkel S, Cafarelli E. Relative changes in maximal force, EMG, and muscle cross-sectional area after isometric training. Med Sci Sports Exerc. 1992;24:1220-1227.
34. Woods D, Hickman M, Jamshidi Y, et al. Elite swimmers and the D allele of the ACE I/D polymorphism. Hum Genet. 2001;108:230-232.
35. Sonna LA, Sharp MA, Knapik JJ, et al. Angiotensin-converting enzyme genotype and physical performance during US Army basic training. J Appl Physiol. 2001;91:1355-1363.
36. Thomis M, Huygens W, Heuninckx S, et al. Exploration of myostatin polymorphisms and the angiotensin-converting enzyme insertion/ deletion genotype in responses of human muscle to strength training. Eur J Appl Physiol. 2004;92:267-274.
37. 2max of Chinese males. Life Sci. 2003;73:2625-2630.
38. Scott RA, Moran C, Wilson RH, et al. No association between angiotensin converting enzyme (ACE) gene variation and endurance athlete status in Kenyans. Comp Biochem Physiol. 2005;141:169-175.
39. Montgomery H, Clarkson P, Barnard M, et al. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet. 1999;353:541-545.
40. Woods DR, World M, Rayson MP, et al. Endurance enhancement related to the human angiotensin I-converting enzyme I-D polymorphism is not due to differences in the cardiorespiratory response to training. Eur J Appl Physiol. 2002;86:240-244.
41. Rennie MJ, Winder WW, Holloszy O. A sparing effect of increased plasma fatty acids on muscle and liver glycogen content in the exercising rat. Biochem J. 1976;156:647-655.
42. Katsuya T, Horiuchi M, Chen YD, et al. Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia. Arterioscler Thromb Vasc Biol 1995;15:779-782.
43. McKenzie CA, Julier C, Forrester T, et al. Segregation and linkage analysis of serum angiotensin I-converting enzyme levels: evidence for two quantitative trait loci. Am J Hum Genet. 1995;57:1426-1435.
44. Bunneman B, Fuxe K, Ganten D. The brain renin-angtiotensin system: localization and general significance. J Cardiovasc Pharm. 1992;19:S51-S62.
45. Levens NR. Local control of jejunal absorption by the renin-angiotensin system. J Cardiovasc Pharm. 1986;8:S17-S22.
46. Jones BH, Standridge MK, Taylor JW, Moustaid N. Angiotensin gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol. 1997;273:R236-R242.
47. Campbell DJ, Kladis A, Duncan AM. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension. 1993;21:155-165.
48. Goldman J, Pfister D, Vulmirovich R. Potentiation of insulin stimulation of hexose transport by kallikrein and bradykinin in isolated rat adipocytes. Mol Cell Endocrinol 1987;50:183-191.
49. Hennes MM, O'Shaughnessy IM, Kelly TM, et al. Insulin-resistant lipolysis in abdominally obese hypertensive individuals: role of the renin-angiotensin system. Hypertension. 1996;28:120-126.
50. Dragovic T, Minshall R, Jackman HL, et al. Kininase II-type enzymes: their putative role in muscle energy metabolism. Diabetes. 1996;45(suppl 1):S34-S37.
51. Henriksen EJ, Jacob S. Effect of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism. 1995;44:267-272.
52. 2max in the sedentary state: the HERITAGE family study. Med Sci Sports Exerc. 1998;30:252-258.
53. Bouchard C. Individual differences in the response to regular exercise. Int J Obes. 1995;19:S5-S8.
54. 2max is associated with ACE genotype in post-menopausal women. J Appl Physiol. 1998;85:1842-1846.
55. Rankinen T, Perusse L, Gagnon J, et al. Angiotensin-converting enzyme ID polymorphism and fitness phenotype in the HERITAGE Family Study. J Appl Physiol. 2000;88:1029-1035.